null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal debt; early-stage clinical-stage biopharma reliant on equity financing; a 20% rate rise has negligible direct interest cost impact but raises dilution cost of future equity raises.

Low direct sensitivity; no significant floating-rate debt, but higher rates compress biotech valuations and increase cost of equity capital needed for ongoing Phase I/II trials.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Active pharmaceutical ingredient (API) sourcing concentrated in India/China; 2) clinical-grade manufacturing reliant on U.S./EU CDMOs with limited redundancy.

Minimal international revenue; primarily U.S.-based clinical operations; sovereign currency devaluation exposure is negligible at current stage.

Operations concentrated in U.S. (California); no material revenue from international markets; currency devaluation risk is essentially zero currently.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

CDMO dependency is high; Kairos likely relies on one or two contract manufacturers for ENX-101 and cirmtuzumab supply, representing non-substitutable near-term production capacity.

Clinical-stage biopharma; no commercial product revenue; cloud infrastructure termination would affect data systems but not core drug development operations critically.

Research and collaboration model; limited digital infrastructure dependency; IT disruption would slow operations but not halt IND-stage clinical programs.

Moderate API coupling risk via CRO and CDMO contracts; switching mid-trial would trigger regulatory revalidation, causing 6–18 month delays and significant cost.

Low Howey Test risk; KAPA stock is a conventional equity security; no token, revenue-sharing instrument, or investment contract structure triggering SEC securities scrutiny beyond standard public-company rules.

Very High

Low-to-moderate; clinical trial data subject to FDA 21 CFR Part 11, HIPAA, and potentially GDPR if EU trial sites used; CCPA exposure minimal given no consumer product.

Negligible antitrust risk; sub-$50M market cap clinical-stage company with no marketed product, no pricing power, and no dominant market position.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Effectively 0% recurring revenue; 100% dependent on grants, licensing milestones, or future product sales; no subscription or retainer revenue currently.

Future monetization via drug licensing deals, partnership milestones, or eventual product commercialization; no current transactional or recurring revenue stream.

No current commercial pricing; future oncology drug pricing will be determined by reimbursement negotiations, competitive landscape, and FDA label; orphan drug designation could support premium pricing.

Potential high pricing power if clinical trials succeed in oncology indications with unmet need; comparable oncology biologics priced $100K–$200K+/year annually.

Biopharmaceutical commercial-stage gross margins typically 70–85%; pre-revenue stage currently; margin realization contingent on successful commercialization.

No free-rider leakage problem; proprietary drug candidates protected by patents and regulatory exclusivity; no open-access or freemium component.

Revenue growth is not headcount-linear; successful drug approval enables highly sublinear scaling via partnerships or licensing; current burn is R&D-weighted, not sales-force-dependent.

Near-zero marginal cost of additional revenue once drug approved and licensed; commercialization via partners would allow revenue scaling without proportional headcount growth.

Not applicable; Kairos Pharma operates no franchise network.

At 10x scale (post-commercialization), customer acquisition cost shifts to oncologist detailing and payer contracting; specialty pharma CAC typically $5K–$15K per prescriber.

No meaningful network effects; drug efficacy and clinical data quality are the moat, not user-base scale; network effect durability rating is not applicable.

AI displacement risk is low for core drug development; AI could accelerate trial design and biomarker analysis but cannot replace FDA-regulated clinical validation processes.

Moderate-to-high recession resistance for oncology therapeutics; cancer treatment demand is largely inelastic, though fundraising and partnership deal-making slow in recessions.

Oncology patients and treating oncologists (end users); future payer/insurer segment for reimbursement; highly concentrated in specialty oncology centers.

Potential licensing or co-development partners (large pharma/biotech); customer concentration risk is extreme—one partnership deal could represent 100% of near-term revenue.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed forward into clinical-stage pipeline (ENX-101, cirmtuzumab); no legacy infrastructure to divest; capex is R&D spend, entirely future-state oriented.

0001962011

KAPA